Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: Investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 8, 2011, Pages 1111-1118

  Abuznait, Alaa H ^a   Cain, Courtney ^b   Ingram, Drury ^b   Burk, David ^b   Kaddoumi, Amal ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; Clearance; P glycoprotein; Up regulation

Indexed keywords

6 CARBOXYFLUORESCEIN; AMYLOID BETA PROTEIN[1-40]; BETA ACTIN; CAFFEINE; DEXAMETHASONE; ESTRADIOL; GLYCOPROTEIN P; HYPERFORIN; IODINE 125; PENTETRAZOLE; RIFAMPICIN; VERAPAMIL;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; EFFUSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; INTRACELLULAR MEMBRANE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; PROTEIN TRANSPORT; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CAFFEINE; CELL LINE; CENTRAL NERVOUS SYSTEM AGENTS; DEXAMETHASONE; ESTRADIOL; HUMANS; P-GLYCOPROTEIN; PENTYLENETETRAZOLE; PHLOROGLUCINOL; RIFAMPIN; STAINING AND LABELING; TERPENES; UP-REGULATION; VERAPAMIL;

EID: 79959863415     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01309.x     Document Type: Article

References (36)

1. Maslow K. 2010 Alzheimer's disease facts and figures. Alzheimers Dement 2010; 6: 158-194.
2. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-766. (Pubitemid 32267077)
3. Zlokovic BV, Frangione B. Transport-clearance hypothesis for Alzheimer's disease and potential therapeutic implications. In: Saido TC, ed. Ab Metabolism in Alzheimer's Disease. Georgetown, TX: Landes Bioscience, 2003: 114-122.
4. Cirrito JR et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 2005; 115: 3285-3290. (Pubitemid 41567593)
5. Vogelgesang S et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002; 12: 535-541. (Pubitemid 35177083)
6. Kuhnke D et al. MDR1-P-Glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides - implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 2007; 17: 347-353. (Pubitemid 47537591)
7. Toornvliet R et al. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 2006; 79: 540-548. (Pubitemid 43841828)
8. Thiebaut F et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
9. Beaulieu E et al. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 1997; 326 (Pt 2): 539-544. (Pubitemid 27417234)
10. Miller DS et al. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 2008; 60: 196-209. (Pubitemid 351962009)
11. Lam FC et al. beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem 2001; 76: 1121-1128.
12. LaRue B et al. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice. J Neurosci Methods 2004; 138: 233-242.
13. Jungbauer LM et al. Preparation of fluorescently-labeled amyloid-beta peptide assemblies: the effect of fluorophore conjugation on structure and function. J Mol Recognit 2009; 22: 403-413.
14. Saido TC. Overview-Abeta metabolism: from Alzheimer research to brain aging control. In: Saido TC, ed. Aβ Metabolism in Alzheimer's Disease. Georgetown, TX: Landes Bioscience, 2003: 1-16.
15. Tom BH et al. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 1976; 12: 180-191.
16. OttMet al. Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR. J Pharmacol Exp Ther 2009; 329: 141-149.
17. Bauer B et al. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the bloodbrain barrier. Mol Pharmacol 2004; 66: 413-419. (Pubitemid 39329239)
18. Perloff MD et al. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 2003; 20: 1177-1183. (Pubitemid 36951842)
19. Haslam IS et al. Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells. Br J Pharmacol 2008; 154: 246-255. (Pubitemid 351620398)
20. Durr D et al. St John's Wort induces intestinal P-glycoprotein/ MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604. (Pubitemid 32059985)
21. Tannergren C et al. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 2004; 75: 298-309. (Pubitemid 38471555)
22. Scheer N et al. In vivo responses of the human and murine pregnane X receptor to dexamethasone in mice. Drug Metab Dispos 2010; 38: 1046-1053.
23. Itkin A et al. Calcium ions promote formation of amyloid beta- Peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. PLoS ONE 2011; 6: e18250.
24. Loeb MB et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc 2004; 52: 381-387. (Pubitemid 38339518)
25. Maia L, de Mendonca A. Does caffeine intake protect from Alzheimer's disease? Eur J Neurol 2002; 9: 377-382. (Pubitemid 35013893)
26. Cao C et al. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis 2009; 17: 681-697.
27. Arendash GW et al. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J Alzheimers Dis 2009; 17: 661-680.
28. Dinamarca MC et al. Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta- deposits. Mol Psychiatry 2006; 11: 1032-1048. (Pubitemid 44631646)
29. Fernandez F et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 2007; 10: 411-413. (Pubitemid 46494581)
30. Pike CJ et al. Protective actions of sex steroid hormones in Alzheimer's disease. Front Neuroendocrinol 2009; 30: 239-258.
31. Popovic M et al. Neuroprotective effect of chronic verapamil treatment on cognitive and noncognitive deficits in an experimental Alzheimer's disease in rats. Int J Neurosci 1997; 92: 79-93.
32. Alisky JM. Intrathecal corticosteroids might slow Alzheimer's disease progression. Neuropsychiatr Dis Treat 2008; 4: 831-833.
33. Liu X et al. Increased P-glycoprotein expression and decreased phenobarbital distribution in the brain of pentylenetetrazole-kindled rats. Neuropharmacology 2007; 53: 657-663. (Pubitemid 47513172)
34. Pham YT et al. Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochim Biophys Acta 2000; 1524: 212-219.
35. Barraud de Lagerie S et al. Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. Br J Pharmacol 2004; 141: 1214-1222.
36. Ma X et al. The pregnane X receptor: from bench to bedside. Expert Opin Drug Metab Toxicol 2008; 4: 895-908.